



FOR IMMEDIATE RELEASE

HEDLEY CHANGES NAME TO BIOSYENT INC. TO REFLECT SHIFT IN STRATEGIC DIRECTION

MISSISSAUGA, ONTARIO (June 13, 2006) Hedley Technologies Inc. (TSX Venture: HED) announced at today's Annual General Meeting that effective immediately the name of the company has been changed to BioSyent Inc. ("BioSyent") and that its trading symbol on the TSX Venture Exchange changes to RX. The change in name reflects the company's forward focus on human health, specifically the pharmaceutical market.

The name change to BioSyent and the change in trading symbol to RX do not affect shareholder's ownership positions in the company and shareholders are not required to take any action with respect to the changes.

On May 9, 2006 the company announced the incorporation of wholly owned subsidiary BioSyent Pharma Inc. ("BioSyent Pharma"). BioSyent Pharma is BioSyent's commercial organization focused on pharmaceutical products. "We are excited by our future" said René Goehrum, Chairman and CEO of BioSyent. "We have adopted a new strategic direction and see significant opportunities in the \$20 billion Canadian pharmaceutical market".

BioSyent continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary HTI Agritech Inc. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

For additional information contact:

René C. Goehrum, Chairman and CEO

rgoehrum@biosyent.com

Tel: (905) 206-0013

www.biosyent.com

Fax: (905) 206-1413

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.